Renuvion Safely and Effectively Treats Lax Skin in Trial
In a Phase II study, the Renuvion device improved the appearance of lax skin in 82.5% of subjects after 6 months.
In a Phase II study, the Renuvion device improved the appearance of lax skin in 82.5% of subjects after 6 months.
AAFPRS President Dr. Patrick Byrne discusses the growing interest in facial cosmetic procedures among male patients and how private practices can adapt to meet their evolving needs.
Regulatory approval allows clinicians to use the biostimulatory filler to treat moderate wrinkles in the chest area.
A report published by Global Industry Analysts expects the global aesthetic services market to hit $23.3 billion by 2026.
Read MoreThanks to a recent viral TikTok video, eyelid lift surgeries may be the next rising trend in plastic surgery.
Read More